close

The Desmond Tutu
HIV Foundation

Pairing rigorous research with community-driven development, the DTHF is making a substantial contribution to service delivery and public health policy relating to HIV, tuberculosis and related infections in South Africa.

About Us Our People

HIV weekly news update in partnership with MedicalBrief

  • MEDICALBRIEF Issue No 0143 - HIV News 23 February 2017

    Isoniazid preventive treatment reduces the risk of death

    A six-month course of isoniazid preventive treatment (IPT) at the beginning of the Temprano trial in Ivory Coast reduced the risk of death by 37% over a mean follow-up period of 4.5 years, Anani Badje from INSERM, Bordeaux, France, reported at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
  • MEDICALBRIEF Issue No 0143 - HIV News 23 February 2017

    One in five ‘heterosexual’ men in the UK got HIV from another man

    A genetic analysis of a large database of UK people with HIV in care shows that 18% of men with HIV who claim to be exclusively heterosexual in fact belong to clusters of linked infections that consist only of men.
  • MEDICALBRIEF Issue No 0143 - HIV News 23 February 2017

    Three-drug regimen beats XDR-TB in first trial

    A regimen of three oral drugs given for six months was enough to clear extensively drug-resistant tuberculosis (XDR-TB) in 29 of the first 31 people to have completed the treatment course, Dr Francesca Conradie of Sizwe Tropical Disease Hospital, Johannesburg, told the 2017 Conference on Retroviruses and Opportunistic Infections.
  • MEDICALBRIEF Issue No 0143 - HIV News 23 February 2017

    Hep C infections drop by half after direct-acting antiviral roll-out

    A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals (DAAs) for the treatment of hepatitis C, researchers have already seen a dramatic decline in acute hepatitis C virus (HCV) infections among one at-risk population, HIV-positive men who have sex with men.
  • MEDICALBRIEF Issue No 0143 - HIV News 23 February 2017

    Tenofovir/emtricitabine/efavirenz less likely to cause adverse birth outcomes

    Infants exposed to an antiretroviral regimen of tenofovir, emtricitabine and efavirenz (Atripla) from conception experienced fewer adverse birth outcomes compared to other three-drug regimens, according to a study of births in Botswana between 2014 and 2016.
View All

Our Research

DTHF NEWS AND EVENTS

DTHF receives the Ubuntu Social Responsibility Award 2017

DTHF received the UBUNTU Award for Social Responsibility at a gala event in Cape Town on 17th February.   The evening …
Read More

The Zimele Project: Launch

This January, there was a buzz of excitement at Philippi Village as 120 new staff members arrived ready to make …
Read More

HIV Vaccine Trial to be launched in South Africa

“We’ve never treated our way out of an epidemic. There’s no doubt we have to have primary prevention alongside treatment …
Read More

9 Steps to an HIV Prevention Revolution in Resource-Limited Settings

It’s 3 decades into the war with HIV/AIDS and so far 78 million have been infected and 39 million people …
Read More

Our Projects

Sensitivity Training

Key Populations Integrated Sensitivity Training Programme The Key Population Research Department leads the development of a health care worker sensitization …
Read More

The Tutu Tester

The Tutu Tester mobile unit provides a free comprehensive health service to under serviced communities. It is in the field …
Read More

Adult HIV Educational Programme

The manual for this distance learning course for doctors and nurses was updated in July 2015 to reflect the latest policies …
Read More

YOUTH CENTRE

Youth Centre
Youth Centre

The DTHF Youth Centre

The DTHF Youth Centre complex in Masiphumelele was built in response to requests from the community for a safe, recreational space for young people. DTHF surveys record a high prevalence of HIV infection among youth in the community.

Visit the Youth Centre

SIGNUP FOR OUR NEWSLETTER: